A clinical study in adults with Growth Hormone Deficiency (GHD) to assess the safety and tolerability of weekly administered TV-1106 (experimental medicinal product) compared to daily administered growth hormone treatment (Genotropin®)
- Conditions
- Growth hormone deficiencyTherapeutic area: Diseases [C] - Hormonal diseases [C19]MedDRA version: 19.0Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disorders
- Registration Number
- EUCTR2014-002736-13-CZ
- Lead Sponsor
- Teva Pharmaceutical Industries Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 140
Patients may be included in the study if they meet all of the following criteria:
a. provision of written informed consent and agreement to comply with study requirements
b. males and females 18 years of age or over
c. body mass index (BMI) between 19 and 35 kg/m2 inclusive
d. diagnosis of adult GHD for at least 6 months, confirmed by medical record diagnostic testing specified by an accepted guidance (eg, Carroll 1998; Cook 2009; Ho 2007; Molitch 2011) in effect at the time of diagnosis or patients who have hypopituitarism from surgical resection
e. treated with a stable dose of daily rhGH for at least 3 months prior to screening
f. IGF-I SDS level between -0.5 and +1.5 at screening
g. stable, adequate doses of replacement hormones (adrenal, thyroid, estrogen, testosterone, vasopressin) for at least 3 months prior to screening as clinically judged by the investigator to be adequate patients who are not receiving glucocorticoid replacement therapy must have adequate adrenal function confirmed by adrenocorticotropic hormone (ACTH) stimulation test at screening
i. women of child-bearing potential must be willing to use a medically accepted method of contraception for the duration of the study and for 30 days after last study treatment. Acceptable methods of contraception include: double barrier method (condom or diaphragm with spermicide), intrauterine device (IUD), partner’s vasectomy, or steroidal contraceptive (oral, transdermal, implanted, injected). Patients who are gonadotropin deficient, surgically sterile, or at least 1 year post-menopausal are not required to use contraception.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 140
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Patients will be excluded from participating in this study if they meet 1 or more of the following criteria:
a. patients with acute or chronic conditions or diseases that could confound results of the study or put the patient at undue risk as determined by the investigator
b. patients who have participated in another clinical trial with a new chemical/biological entity within 3 months of screening
c. patients with known active malignancy (excluding surgically removed basal cell carcinoma or carcinoma in situ of cervix)
d. patients with a previously treated pituitary tumor with evidence of tumor progression in the past year (evidence will be established by magnetic resonance imaging [MRI] or computerized tomography [CT] obtained within 3 months of screening or at screening. Patients will be excluded if they show any progression from a prior scan taken at least 12 months prior to the current scan).
e. patients with a new diagnosis of pituitary adenoma or other intracranial tumor within 12 months of screening
f. presence of Prader-Willi syndrome, Turner’s syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active Cushing’s syndrome in the past year.
g. patients with known allergy or hypersensitivity to rhGH, human serum albumin (HSA), yeast-derived products, or any other component of the formulation
h. patients with previous signs or history of increased intracranial pressure (ICP) with rhGH treatment, or documented ICP or signs of ICP on fundoscopic examination at the time of screening (may be performed by investigator or referred to an ophthalmologist) (patients with previous history of ICP due to treated tumors that have resolved can be included in the study.)
i. patients with severe, clinically significant, persistent or recurring migraines, edema, or history or presence of carpal tunnel syndrome, or other nerve compression symptoms assessed as clinically important by the investigator
j. patients with untreated or poorly controlled stage 2 hypertension (systolic blood pressure [SBP] =150 mmHg and/or diastolic blood pressure [DBP] =90 mmHg).
k. patients with clinically significant abnormalities on the screening laboratory assessments, electrocardiogram (ECG), or physical examination that would confound the interpretation of the study or put the patient at undue risk of participation in the study as determined by the investigator
l. patients with type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus as indicated by a glycated hemoglobin (HbA1c) =8%
m. patients who use anabolic steroids or corticosteroids, except for physiological maintenance doses used as treatment for patients with hormone deficiencies (limited use of low dose glucocorticoid preparations is allowed [eg, topical preparations]; inhaled budesonide will be permitted at a dose not to exceed 400 µg/day for 3 days [total <1200 µg/month] or equivalent.)
n. patients using weight reducing agents or appetite suppressants
o. women who are pregnant or nursing, or planning pregnancy during the study period
p. patients with active or known history of substance abuse that in the investigator’s opinion would affect compliance with the study
q. patients with known tendency to have injection site lipoatrophy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method